IP Library › Granted Patent US 12,220,424
Granted Patent B2
US 12,220,424 · App. 17/497,392 · Granted Feb 11, 2025

Compositions comprising nicotinamide riboside and a urolithin

Inventors: Penelope Andreux (Eclepens, CH); Christopher L. Rinsch (Lausanne, CH)
Assignee: Amazentis SA
A61K31/706A23L29/00A23L33/10A61K9/0053A61K31/366A61P21/00A61P25/28A23V2002/00A23V2200/316A23V2200/322A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,220,424
App. No.
17/497,392
Granted
Feb 11, 2025
Kind
B2
Abstract

A composition comprising: a) nicotinamide riboside and b) a urolithin which is a compound of formula (I) or a salt thereof: wherein: A, B, C and D are each independently selected from H and OH; W, X and Y are each independently selected from H and OH; and Z is selected from H and OH. The compositions are useful as medicaments, for example for treating muscle-related pathological conditions, neurodegenerative diseases, and/or mitochondrial diseases and as dietary supplements, functional foods and beverages, and specialised nutrition or medical foods.

Claims (13)

1. A method of improving, maintaining, enhancing, increasing, or promoting mitochondrial function or activity, comprising administering to a subject in need thereof an effective amount of a composition comprising:

a) nicotinamide riboside; and

b) urolithin A or a salt thereof;

wherein the nicotinamide riboside is present in an amount of 20 mg to 5 g; and the urolithin A is present in an amount of 10 mg to 5 g.

2. The method of claim 1 , wherein the composition is formulated as a solid, a semi-solid, a powder, or a liquid.

3. The method of claim 1 , wherein the composition is formulated as a medicament, dietary supplement, functional food, functional beverage, specialized nutrition, or medical food.

4. The method of claim 1 , wherein mitochondrial function or activity is improved.

5. The method of claim 1 , wherein mitochondrial function or activity is maintained.

6. The method of claim 1 , wherein mitochondrial function or activity is enhanced.

7. The method of claim 1 , wherein mitochondrial function or activity is increased.

8. The method of claim 1 , wherein mitochondrial function or activity is promoted.

9. The method of claim 1 , wherein mitochondrial biogenesis is increased.

10. The method of claim 1 , wherein physical endurance is improved, physical fatigue is inhibited or reduced, blood oxygen levels are enhanced, energy in healthy individuals is enhanced, working capacity and endurance is enhanced, muscle fatigue is reduced, muscle ATP levels are increased, or lactic acid in blood is reduced.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2023
From: ANDREUX, PENELOPE; RINSCH, CHRISTOPHER L.
To: AMAZENTIS SA
Reel/Frame 065337/0645 →
Priority Claims (2)
GB 1522892 · Dec 24, 2015 · national
GB 1611960 · Jul 8, 2016 · national
Continuity (2)
Continuation 16064922
Related Publication 20220105117A1 · Apr 7, 2022
References Cited (13)
US 11166972B2 · Rinsch et al. · 2021 [cited by applicant]
US 20120164243A1 · Rinsch et al. · 2012 [cited by applicant]
WO WO2007008548A2 · 2007 [cited by applicant]
WO WO2014111580A1 · 2014 [cited by applicant]
WO WO2015097231A1 · 2015 [cited by applicant]
Burattini et al., “C2C12 murine myoblasts as a model of skeletal muscle development: morpho-functional characterization,” European Journal of Histochemistry, 48(3):223-234 (2004). [cited by applicant]
Chen et al., “Decreased heat shock protein 27 expression and altered autophagy in human cells harboring A8322G mitochondrial DNA mutation,” Mitochondrion, 11:739-749 (2011). [cited by applicant]
Forterre et al., “Proteomic Analysis of C2C12 Myoblast and Myotube Exosome-Like Vesicles: A New Paradigm for Myoblast-Myotube Cross Talk?” PLoS One 9(1): e84153 (2014). [cited by applicant]
International Search Report for International Application No. PCT/EP2016/082596 mailed Apr. 2005. [cited by applicant]
Kahn et al., “Effective Treatment of Mitochondrial Myopathy by Nicotinamide Ribose, a Vitamin B3,” Embo Molecular Medicine, vol. 6, (2014). [cited by applicant]
Peng et al., “Inhibiting cytosolic translation and autophagy improves health in mitochoncrial disease,” Human Molecular Genetics, 24(17):4829-4847 (2015). [cited by applicant]
Tirziu et al., “Cell Communications in the Heart,” Circulation, 122(9): 928-937 (2010). [cited by applicant]
Yuan et al., “Mitochondrial myopathy with autophagic vacuoles in patients with the m.8344A>G mutation,” J Clin Pathol, 66:659-664 (2013). [cited by applicant]
Cited By (3)
US 12,544,358 US 12,576,064 US 12,576,065